Sight Sciences announces publication of 24-month results of SAHARA RCT

Sight Sciences (SGHT) announced that the manuscript detailing 24-month results from Stage 3 of the SAHARA randomized controlled trial, RCT, has been published ahead of print, PAP, by Optometry and Vision Science. All mean signs and symptoms remained statistically significantly better than the study baseline at all time points measured through the end of the study at 24 months. The majority of participants who received treatment for dry eye disease with the TearCare System at baseline and again at Month 5 required no additional treatment based on pre-defined retreatment criteria. SAHARA RCT 24-Month Stage 3 Results: Tear breakup time remained statistically significantly better than study baseline for all subjects through Month 24; Meibum quality and quantity as measured by Meibomian Gland Secretion Score showed that the improvement from baseline observed at Month 6 following two TearCare treatments was maintained through 24 months for all subjects; The number of meibomian glands yielding any liquid and number of glands yielding clear liquid also showed clinically meaningful and statistically significant improvement at Month 6; Results from the first 6 months of the SAHARA RCT demonstrated that interventional eyelid procedures enabled by TearCare were superior to twice daily use of Restasis